ReviewCancers2021
Dose-Response Effect and Dose-Toxicity in Stereotactic Radiotherapy for Brain Metastases: A Review.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- Modeling dose to normal brain following hypofractionated stereotactic radiotherapy to a single brain metastasis.Journal of applied clinical medical physics · 2026Article
- Multicenter evaluation of planning quality in intracranial stereotactic radiotherapy for brain metastases.Physics and imaging in radiation oncology · 2026Article
- A mouse model of stereotactic radiosurgery-induced neuroinflammation and blood-brain barrier compromise.Acta neuropathologica communications · 2025Article
- Stereotactic radiotherapy for brain metastases of non-small cell lung cancer: A comprehensive review.World journal of radiology · 2025Review
- Article
- Article
- Stereotactic radiosurgery for multiple small brain metastases using gamma knife versus single-isocenter VMAT: Normal brain dose based on lesion number and size.Journal of applied clinical medical physics · 2025Article
- Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial.EClinicalMedicine · 2025Article
- Article
- Advancements in Imaging and Neurosurgical Techniques for Brain Tumor Resection: A Comprehensive Review.Cureus · 2024Review
- Dosimetric and Clinical Prognostic Factors in Single-Isocenter Linac-Based Stereotactic Radiotherapy for Brain Metastases.Cancers · 2024Article
- Lymphopenia associated with whole-brain radiotherapy and its effects on clinical outcomes of patients with brain metastases.Scientific reports · 2024Article
- Effect of different optimization parameters in single isocenter multiple brain metastases radiosurgery.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Article
- How Does the Number of Brain Metastases Correlate With Normal Brain Exposure in Single-Isocenter Multitarget Multifraction Stereotactic Radiosurgery.Advances in radiation oncology · 2024Article
- Article
- The dosimetric parameters impact on local recurrence in stereotactic radiotherapy for brain metastases.The British journal of radiology · 2024Article
- Article
- Biomedical advances and future prospects of high-precision three-dimensional radiotherapy and four-dimensional radiotherapy.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For more than two decades, stereotactic radiosurgery has been considered a cornerstone treatment for patients with limited brain metastases. Historically, radiosurgery in a single fraction has been the standard of care but recent technical advances have also enabled the delivery of hypofractionated stereotactic radiotherapy for dedicated situations. Only few studies have investigated the efficacy and toxicity profile of different hypofractionated schedules but, to date, the ideal dose and fractionation schedule still remains unknown. Moreover, the linear-quadratic model is being debated regarding high dose per fraction. Recent studies shown the radiation schedule is a critical factor in the immunomodulatory responses. The aim of this literature review was to discuss the dose-effect relation in brain metastases treated by stereotactic radiosurgery accounting for fractionation and technical considerations. Efficacy and toxicity data were analyzed in the light of recent published data. Only retrospective and heterogeneous data were available. We attempted to present the relevant data with caution. A BED10 of 40 to 50 Gy seems associated with a 12-month local control rate >70%. A BED10 of 50 to 60 Gy seems to achieve a 12-month local control rate at least of 80% at 12 months. In the brain metastases radiosurgery series, for single-fraction schedule, a V12 Gy < 5 to 10 cc was associated to 7.1-22.5% radionecrosis rate. For three-fractions schedule, V18 Gy < 26-30 cc, V21 Gy < 21 cc and V23 Gy < 5-7 cc were associated with about 0-14% radionecrosis rate. For five-fractions schedule, V30 Gy < 10-30 cc, V 28.8 Gy < 3-7 cc and V25 Gy < 16 cc were associated with about 2-14% symptomatic radionecrosis rate. There are still no prospective trials comparing radiosurgery to fractionated stereotactic irradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.